Self-efficacy and compliance with benzodiazepine taper in older adults with chronic insomnia.

Better understanding of compliance with BZD taper is warranted. Compliance with a taper program and perceived self-efficacy (SE) in being able to comply with hypnotic reduction goals was monitored weekly in 52 older adults (mean age: 63.0 years) with chronic insomnia (average duration: 21.9 years) who underwent a 10-week physician-supervised medication tapering. One group received cognitive- behavior therapy for insomnia during discontinuation, whereas the other did not. Compliant patients showed higher SE ratings at Weeks 6, 8, 9, and 10. Medication-free patients at the end of the treatment also reported higher mean SE ratings at those 4 weeks. Differences remained significant when withdrawal symptoms and sleep efficiency were controlled for. These results have important clinical implications because SE may indicate key time points when patients are experiencing more difficulty during discontinuation.     

Presidential Address: 21st International Congress of Applied Psychology

In 1920, 66 years ago, in Geneva, on Claparede's initiative, 16 psychologists coming from 7 countries met to discuss "Nature and Nurture in Aptitude Development". They had a fruitful meeting, decided to create IAAP, and immediately started to organise the second Congress of Applied Psychology which took place in Barcelona in 1921. IAAP is, therefore, the oldest international association of psychologists. Thirty-five years later, and after a period of inactivity due to the war, there was a big step forward. Five hundred psychologists from 29 countries met in London for the 12th IAAP Congress, and Dr. Frisby, opening the Congress, could already take pride in the diversification of our field, quoting educational, clinical and social issues.     

Die akute Therapie des ischämischen Schlaganfalles

Seit Etablierung unserer ersten Stroke Units als Spezialstationen zur Akutbehandlung von Schlaganfallpatienten 1996 und 1998 sind die Herausforderungen an das Management im Bereich der akuten Schlaganfalltherapie durch steigende Patientenzahlen, zunehmende Lyseraten und abnehmende Liegedauer in Kombination mit neuen, Erfolg versprechenden Therapieoptionen stetig angestiegen.